Cargando…

Targeting NSD2-mediated SRC-3 liquid–liquid phase separation sensitizes bortezomib treatment in multiple myeloma

Development of chemoresistance is the main reason for failure of clinical management of multiple myeloma (MM), but the genetic and epigenetic aberrations that interact to confer such chemoresistance remains unknown. In the present study, we find that high steroid receptor coactivator-3 (SRC-3) expre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Jing, Xie, Ying, Guo, Jing, Li, Xin, Wang, Jingjing, Jiang, Hongmei, Peng, Ziyi, Wang, Jingya, Wang, Sheng, Li, Qian, Ye, Linquan, Zhong, Yuping, Zhang, Qiguo, Liu, Xiaozhi, Lonard, David M., Wang, Jin, O’Malley, Bert W., Liu, Zhiqiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884723/ https://www.ncbi.nlm.nih.gov/pubmed/33589584 http://dx.doi.org/10.1038/s41467-021-21386-y

Ejemplares similares

Posttranslational modification of Aurora A‐NSD2 loop contributes to drug resistance in t(4;14) multiple myeloma
por: Jiang, Hongmei, et al.
Publicado: (2022)

All-trans retinoic acid improves NSD2-mediated RARα phase separation and efficacy of anti-CD38 CAR T-cell therapy in multiple myeloma
por: Peng, Ziyi, et al.
Publicado: (2023)

Melatonin enhances osteoblastogenesis of senescent bone marrow stromal cells through NSD2‐mediated chromatin remodelling
por: Xie, Ying, et al.
Publicado: (2022)

Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma
por: Bijou, Imani, et al.
Publicado: (2023)

Tumor Suppressor Role for the SPOP Ubiquitin Ligase in Signal-Dependent Proteolysis of the Oncogenic Coactivator SRC-3/AIB1
por: Li, Chao, et al.
Publicado: (2011)

Hypoxia-induced CREB cooperates MMSET to modify chromatin and promote DKK1 expression in multiple myeloma
por: Xu, Yinyin, et al.
Publicado: (2021)

SRC-2 Coactivator: a role in human metabolic evolution and disease
por: O’Malley, Bert W.
Publicado: (2020)

A genome-scale CRISPR Cas9 dropout screen identifies synthetically lethal targets in SRC-3 inhibited cancer cells
por: Gilad, Yosi, et al.
Publicado: (2021)

Steroid Receptor Coactivator-3 (SRC-3/AIB1) as a Novel Therapeutic Target in Triple Negative Breast Cancer and Its Inhibition with a Phospho-Bufalin Prodrug
por: Song, Xianzhou, et al.
Publicado: (2015)

Steroid receptor coactivator 3 (SRC-3/AIB1) is enriched and functional in mouse and human Tregs
por: Nikolai, Bryan C., et al.
Publicado: (2021)

Steroid receptor coactivators – their role in immunity
por: Gilad, Yosi, et al.
Publicado: (2022)

Deacetylation induced nuclear condensation of HP1γ promotes multiple myeloma drug resistance
por: Li, Xin, et al.
Publicado: (2023)

Wound Healing-related Functions of the p160 Steroid Receptor Coactivator Family
por: Mullany, Lisa K, et al.
Publicado: (2020)

Enhancer–promoter entanglement explains their transcriptional interdependence
por: Panigrahi, Anil K., et al.
Publicado: (2023)

Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications
por: Alwahsh, Mohammad, et al.
Publicado: (2023)

Steroid receptor coactivator-3 inhibition generates breast cancer antitumor immune microenvironment
por: Han, Sang Jun, et al.
Publicado: (2022)

Drug Combination in Cancer Treatment—From Cocktails to Conjugated Combinations
por: Gilad, Yosi, et al.
Publicado: (2021)

PHLPP Sensitizes Multiple Myeloma Cells to Bortezomib Through Regulating LAMP2
por: Liu, Xiao, et al.
Publicado: (2020)

Periplocin Overcomes Bortezomib Resistance by Suppressing the Growth and Down-Regulation of Cell Adhesion Molecules in Multiple Myeloma
por: Aziz, Abdul, et al.
Publicado: (2023)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L
por: Morishita, Masayo, et al.
Publicado: (2014)

Epigenomic reprogramming via HRP2-MINA dictates response to proteasome inhibitors in multiple myeloma with t(4;14) translocation
por: Wang, Jingjing, et al.
Publicado: (2022)

Anti-β(2)-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy
por: Zhang, Mingjun, et al.
Publicado: (2015)

Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma
por: He, Chao, et al.
Publicado: (2019)

BAFF is involved in macrophage-induced bortezomib resistance in myeloma
por: Chen, Jing, et al.
Publicado: (2017)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Low expression of NSD1, NSD2, and NSD3 define a subset of human papillomavirus-positive oral squamous carcinomas with unfavorable prognosis
por: Gameiro, Steven F., et al.
Publicado: (2021)

Immunohistochemistry for identification of CCND1, NSD2, and MAF gene rearrangements in plasma cell myeloma
por: Murase, Takayuki, et al.
Publicado: (2019)

LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p
por: Pan, Yafang, et al.
Publicado: (2019)

Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination
por: Gilad, Yosi, et al.
Publicado: (2019)

Author Correction: Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination
por: Gilad, Yosi, et al.
Publicado: (2020)

Lycorine Downregulates HMGB1 to Inhibit Autophagy and Enhances Bortezomib Activity in Multiple Myeloma
por: Roy, Mridul, et al.
Publicado: (2016)

Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor in Multiple Myeloma
por: Wang, Yafei, et al.
Publicado: (2022)

C-reactive protein impairs immune response of CD8(+) T cells via FcγRIIb-p38MAPK-ROS axis in multiple myeloma
por: Jiang, Jinxing, et al.
Publicado: (2023)

TRIM21 enhances bortezomib sensitivity in multiple myeloma by halting prosurvival autophagy
por: Chen, Jing, et al.
Publicado: (2023)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients
por: Wang, Hua, et al.
Publicado: (2016)

Clinical outcomes of bortezomib-based therapy in myeloma
por: Djebbari, Faouzi, et al.
Publicado: (2018)

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
por: Di Lernia, Giuseppe, et al.
Publicado: (2020)

Entinostat-Bortezomib Hybrids against Multiple Myeloma
por: Ferro, Angelica, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_60olvein8gf4vvrmdvkf5usi66